Neuro-oncology advances

Keyphrases

Publications

volume 6, number 1, 2024

Ben Ho, Anthony Arnoldo, Yvonne Zhong, Mei Lu, Jonathon Torchia, Fupan Yao, Cynthia Hawkins, Annie Huang
Rapid, economical diagnostic classification of ATRT molecular subgroup using NanoString nCounter platform. Neuro-oncology advances 6 (1) (2024)
Lei He, Hong Zhang, Tianshi Li, Jianing Yang, Yanpeng Zhou, Jiaxiang Wang, Tuerhong Saidaer, Xiaoyan Bai, Xing Liu, Yinyan Wang, Lei Wang
Identifying IDH-mutant and 1p/19q noncodeleted astrocytomas from nonenhancing gliomas: Manual recognition followed by artificial intelligence recognition. Neuro-oncology advances 6 (1) (2024)
Victor Gabriel El-Hajj, Abdul Karim Ghaith, Ryan H Nguyen, Neil Nazar Al-Saidi, Harry Hoang, Stephen P Graepel, Adrian Elmi Terander, Eric J Lehrer, Paul Brown, Mohamad Bydon
Analysis of demographics and the impact of adjuvant radiotherapy on a nationwide cohort of patients with high-grade spinal meningiomas. Neuro-oncology advances 6 (1) (2024)
Claudio Esteves Tatsui, Kristen W Carlson, Chirag B Patel
Tumor treating fields (TTFields) for spinal metastasis-The case for bone removal and spinal implants as waveguides to enhance field strength at the target. Neuro-oncology advances 6 (1) (2024)
Emily J Smith, Anant Naik, Mahima Goel, Patrick Y Wen, Michael Lim, Susan M Chang, Isabelle M Germano
Adult neuro-oncology trials in the United States over 5 decades: Analysis of trials completion rate to guide the path forward. Neuro-oncology advances 6 (1) (2024)
Ashley R Tetens, Allison M Martin, Antje Arnold, Orlandi V Novak, Adrian Idrizi, Rakel Tryggvadottir, Jordyn Craig-Schwartz, Athanasia Liapodimitri, Kayleigh Lunsford, Michael I Barbato, Charles G Eberhart, Adam C Resnick, Eric H Raabe, Michael A Koldobskiy
DNA methylation landscapes in DIPG reveal methylome variability that can be modified pharmacologically. Neuro-oncology advances 6 (1) (2024)
Riley K Driscoll, Seán B Lyne, David J Voce, Stefania Maraka, Vinai Gondi, Steven J Chmura, Karan S Dixit, Priya U Kumthekar, Theodore G Karrison, Peter Pytel, John M Collins, Roger Stupp, Ryan T Merrell, Rimas V Lukas, Bakhtiar Yamini
A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT -methylated malignant glioma. Neuro-oncology advances 6 (1) (2024)
Nicole Briceno, Elizabeth Vera, Edina Komlodi-Pasztor, Zied Abdullaev, Anna Choi, Ewa Grajkowska, Tricia Kunst, Jason Levine, Matthew Lindsley, Kelly Fernandez, Jennifer Reyes, Lisa Boris, Eric Burton, Marissa Panzer, Lily Polskin, Marta Penas-Prado, Tina Pillai, Brett J Theeler, Jing Wu, Kathleen Wall, Antonios Papanicolau-Sengos, Martha Quezado, James Smirniotopoulos, Kenneth D Aldape, Terri S Armstrong, Mark R Gilbert
Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings. Neuro-oncology advances 6 (1) (2024)
Olha Krynina, Teresita Díaz de Ståhl, Cecilia Jylhä, Cecilia Arthur, Geraldine Giraud, Per Nyman, Anders Fritzberg, Johanna Sandgren, Emma Tham, Ulrika Sandvik
The potential of liquid biopsy for detection of the KIAA1549-BRAF fusion in circulating tumor DNA from children with pilocytic astrocytoma. Neuro-oncology advances 6 (1) (2024)
Zhi-Feng Shi, Kay Ka-Wai Li, Danny Tat-Ming Chan, Ying Mao, Ho-Keung Ng
Alternative lengthening of telomeres is seen in a proportion of oligodendrogliomas and is associated with a worse prognosis. Neuro-oncology advances 6 (1) (2024)
Kira Tosefsky, Karina Chornenka Martin, Alexander D Rebchuk, Justin Z Wang, Farshad Nassiri, Amy Lum, Gelareh Zadeh, Serge Makarenko, Stephen Yip
Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting CDKN2A/B status. Neuro-oncology advances 6 (1) (2024)
Matthijs van der Meulen, Ronald C Ramos, Mathew R Voisin, Vikas Patil, Qingxia Wei, Olivia Singh, Seth A Climans, Navya Kalidindi, Rosemarylin Or, Ken Aldape, Phedias Diamandis, David G Munoz, Gelareh Zadeh, Warren P Mason
Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma. Neuro-oncology advances 6 (1) (2024)
Srirupa Bhattacharyya, Janet L Oblinger, Roberta L Beauchamp, Lili Kosa, Francis Robert, Scott R Plotkin, Long-Sheng Chang, Vijaya Ramesh
Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2 -deficient models. Neuro-oncology advances 6 (1) (2024)
Inka Ristow, Michael G Kaul, Maria Stark, Antonia Zapf, Christoph Riedel, Alexander Lenz, Victor F Mautner, Said C Farschtschi, Ivayla Apostolova, Gerhard Adam, Peter Bannas, Johannes Salamon, Lennart Well
Discrimination of benign, atypical, and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 using diffusion-weighted MRI. Neuro-oncology advances 6 (1) (2024)
Anne E M Leenders, Eva Kremer-Hooft van Huijsduijnen, Bruno Robalo, Rosa van Male, Alberto De Luca, Rachèl Kemps, Eelco Wieger Hoving, Maarten H Lequin, Martha A Grootenhuis, Marita Partanen
Unraveling the relations between post-traumatic stress symptoms, neurocognitive functioning, and limbic white matter in pediatric brain tumor patients. Neuro-oncology advances 6 (1) (2024)
Kanchi Shah, Vinayak Bhartia, Chandrima Biswas, Arpita Sahu, Prakash M Shetty, Vikas Singh, Parthiban Velayutham, Suyash P Awate, Aliasgar V Moiyadi
Tumor location and neurocognitive function-Unravelling the association and identifying relevant anatomical substrates in intra-axial brain tumors. Neuro-oncology advances 6 (1) (2024)
Riley K Driscoll, Seán B Lyne, David J Voce, Stefania Maraka, Vinai Gondi, Steven J Chmura, Karan S Dixit, Priya U Kumthekar, Theodore G Karrison, Peter Pytel, John M Collins, Roger Stupp, Ryan T Merrell, Rimas V Lukas, Bakhtiar Yamini
A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT -methylated malignant glioma. Neuro-oncology advances 6 (1) (2024)
Takahiro Sanada, Manabu Kinoshita, Takahiro Sasaki, Shota Yamamoto, Seiya Fujikawa, Shusei Fukuyama, Nobuhide Hayashi, Junya Fukai, Yoshiko Okita, Masahiro Nonaka, Takehiro Uda, Hideyuki Arita, Kanji Mori, Kenichi Ishibashi, Koji Takano, Namiko Nishida, Tomoko Shofuda, Ema Yoshioka, Daisuke Kanematsu, Mishie Tanino, Yoshinori Kodama, Masayuki Mano, Yonehiro Kanemura
Prediction of MGMT promotor methylation status in glioblastoma by contrast-enhanced T1-weighted intensity image. Neuro-oncology advances 6 (1) (2024)
Ashley R Tetens, Allison M Martin, Antje Arnold, Orlandi V Novak, Adrian Idrizi, Rakel Tryggvadottir, Jordyn Craig-Schwartz, Athanasia Liapodimitri, Kayleigh Lunsford, Michael I Barbato, Charles G Eberhart, Adam C Resnick, Eric H Raabe, Michael A Koldobskiy
DNA methylation landscapes in DIPG reveal methylome variability that can be modified pharmacologically. Neuro-oncology advances 6 (1) (2024)
Samuel A Goldlust, Louis Burt Nabors, Sigmund Hsu, Nimish Mohile, Paul J Duic, Tara Benkers, Samuel Singer, Mayank Rao, Lori Cappello, Sandra L Silberman, George Farmer
Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma. Neuro-oncology advances 6 (1) (2024)
Sé Maria Frances, Louise Murray, Emma Nicklin, Galina Velikova, Florien W Boele
Long-term health-related quality of life in meningioma survivors: A mixed-methods systematic review. Neuro-oncology advances 6 (1) (2024)
Matthijs van der Meulen, Ronald C Ramos, Mathew R Voisin, Vikas Patil, Qingxia Wei, Olivia Singh, Seth A Climans, Navya Kalidindi, Rosemarylin Or, Ken Aldape, Phedias Diamandis, David G Munoz, Gelareh Zadeh, Warren P Mason
Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma. Neuro-oncology advances 6 (1) (2024)
Giacomo Sferruzza, Massimo Malcangi, Luca Bosco, Gaetano Finocchiaro
Reassessing the efficacy of bevacizumab in newly diagnosed glioblastoma: A systematic review and external pseudodata-based analysis. Neuro-oncology advances 6 (1) (2024)
Emily J Smith, Anant Naik, Mahima Goel, Patrick Y Wen, Michael Lim, Susan M Chang, Isabelle M Germano
Adult neuro-oncology trials in the United States over 5 decades: Analysis of trials completion rate to guide the path forward. Neuro-oncology advances 6 (1) (2024)
Angelo Dipasquale, Enrico Franceschi, Giuseppe Lombardi, Matteo Simonelli
Vorasidenib in IDH mutant WHO grade 2 gliomas: time to stop sitting on the fence? Neuro-oncology advances 6 (1) (2024)
Kira Tosefsky, Karina Chornenka Martin, Alexander D Rebchuk, Justin Z Wang, Farshad Nassiri, Amy Lum, Gelareh Zadeh, Serge Makarenko, Stephen Yip
Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting CDKN2A/B status. Neuro-oncology advances 6 (1) (2024)
Ben Ho, Anthony Arnoldo, Yvonne Zhong, Mei Lu, Jonathon Torchia, Fupan Yao, Cynthia Hawkins, Annie Huang
Rapid, economical diagnostic classification of ATRT molecular subgroup using NanoString nCounter platform. Neuro-oncology advances 6 (1) (2024)
Gino Cioffi, Kristin A Waite, Mantas Dmukauskas, Michael Glantz, Sonikpreet Aulakh, Theodore Nicolaides, Soma Sengupta, Joanne Xiu, Jill S Barnholtz-Sloan
Sex differences in glioblastoma response to treatment: Impact of MGMT methylation. Neuro-oncology advances 6 (1) (2024)
Claudio Esteves Tatsui, Kristen W Carlson, Chirag B Patel
Tumor treating fields (TTFields) for spinal metastasis-The case for bone removal and spinal implants as waveguides to enhance field strength at the target. Neuro-oncology advances 6 (1) (2024)
Anne E M Leenders, Eva Kremer-Hooft van Huijsduijnen, Bruno Robalo, Rosa van Male, Alberto De Luca, Rachèl Kemps, Eelco Wieger Hoving, Maarten H Lequin, Martha A Grootenhuis, Marita Partanen
Unraveling the relations between post-traumatic stress symptoms, neurocognitive functioning, and limbic white matter in pediatric brain tumor patients. Neuro-oncology advances 6 (1) (2024)
Srirupa Bhattacharyya, Janet L Oblinger, Roberta L Beauchamp, Lili Kosa, Francis Robert, Scott R Plotkin, Long-Sheng Chang, Vijaya Ramesh
Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2 -deficient models. Neuro-oncology advances 6 (1) (2024)
Gino Cioffi, Kristin A Waite, Mantas Dmukauskas, Michael Glantz, Sonikpreet Aulakh, Theodore Nicolaides, Soma Sengupta, Joanne Xiu, Jill S Barnholtz-Sloan
Sex differences in glioblastoma response to treatment: Impact of MGMT methylation. Neuro-oncology advances 6 (1) (2024)
Inka Ristow, Michael G Kaul, Maria Stark, Antonia Zapf, Christoph Riedel, Alexander Lenz, Victor F Mautner, Said C Farschtschi, Ivayla Apostolova, Gerhard Adam, Peter Bannas, Johannes Salamon, Lennart Well
Discrimination of benign, atypical, and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 using diffusion-weighted MRI. Neuro-oncology advances 6 (1) (2024)
Michael Goutnik, Alexandria Iakovidis, Megan E H Still, Rachel S F Moor, Kaitlyn Melnick, Sandra Yan, Muhammad Abbas, Jianping Huang, Ashley P Ghiaseddin
Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions. Neuro-oncology advances 6 (1) (2024)
Kayla Prezelski, Dylan G Hsu, Luke Del Balzo, Erica Heller, Jennifer Ma, Luke R G Pike, Åse Ballangrud, Michalis Aristophanous
Artificial-intelligence-driven measurements of brain metastases' response to SRS compare favorably with current manual standards of assessment. Neuro-oncology advances 6 (1) (2024)
Kanchi Shah, Vinayak Bhartia, Chandrima Biswas, Arpita Sahu, Prakash M Shetty, Vikas Singh, Parthiban Velayutham, Suyash P Awate, Aliasgar V Moiyadi
Tumor location and neurocognitive function-Unravelling the association and identifying relevant anatomical substrates in intra-axial brain tumors. Neuro-oncology advances 6 (1) (2024)
Nicole Briceno, Elizabeth Vera, Edina Komlodi-Pasztor, Zied Abdullaev, Anna Choi, Ewa Grajkowska, Tricia Kunst, Jason Levine, Matthew Lindsley, Kelly Fernandez, Jennifer Reyes, Lisa Boris, Eric Burton, Marissa Panzer, Lily Polskin, Marta Penas-Prado, Tina Pillai, Brett J Theeler, Jing Wu, Kathleen Wall, Antonios Papanicolau-Sengos, Martha Quezado, James Smirniotopoulos, Kenneth D Aldape, Terri S Armstrong, Mark R Gilbert
Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings. Neuro-oncology advances 6 (1) (2024)
Kayla Prezelski, Dylan G Hsu, Luke Del Balzo, Erica Heller, Jennifer Ma, Luke R G Pike, Åse Ballangrud, Michalis Aristophanous
Artificial-intelligence-driven measurements of brain metastases' response to SRS compare favorably with current manual standards of assessment. Neuro-oncology advances 6 (1) (2024)
Victor Gabriel El-Hajj, Abdul Karim Ghaith, Ryan H Nguyen, Neil Nazar Al-Saidi, Harry Hoang, Stephen P Graepel, Adrian Elmi Terander, Eric J Lehrer, Paul Brown, Mohamad Bydon
Analysis of demographics and the impact of adjuvant radiotherapy on a nationwide cohort of patients with high-grade spinal meningiomas. Neuro-oncology advances 6 (1) (2024)
Takahiro Sanada, Manabu Kinoshita, Takahiro Sasaki, Shota Yamamoto, Seiya Fujikawa, Shusei Fukuyama, Nobuhide Hayashi, Junya Fukai, Yoshiko Okita, Masahiro Nonaka, Takehiro Uda, Hideyuki Arita, Kanji Mori, Kenichi Ishibashi, Koji Takano, Namiko Nishida, Tomoko Shofuda, Ema Yoshioka, Daisuke Kanematsu, Mishie Tanino, Yoshinori Kodama, Masayuki Mano, Yonehiro Kanemura
Prediction of MGMT promotor methylation status in glioblastoma by contrast-enhanced T1-weighted intensity image. Neuro-oncology advances 6 (1) (2024)
Lei He, Hong Zhang, Tianshi Li, Jianing Yang, Yanpeng Zhou, Jiaxiang Wang, Tuerhong Saidaer, Xiaoyan Bai, Xing Liu, Yinyan Wang, Lei Wang
Identifying IDH-mutant and 1p/19q noncodeleted astrocytomas from nonenhancing gliomas: Manual recognition followed by artificial intelligence recognition. Neuro-oncology advances 6 (1) (2024)
Michael Goutnik, Alexandria Iakovidis, Megan E H Still, Rachel S F Moor, Kaitlyn Melnick, Sandra Yan, Muhammad Abbas, Jianping Huang, Ashley P Ghiaseddin
Advancements in chimeric antigen receptor-expressing T-cell therapy for glioblastoma multiforme: Literature review and future directions. Neuro-oncology advances 6 (1) (2024)
Zhi-Feng Shi, Kay Ka-Wai Li, Danny Tat-Ming Chan, Ying Mao, Ho-Keung Ng
Alternative lengthening of telomeres is seen in a proportion of oligodendrogliomas and is associated with a worse prognosis. Neuro-oncology advances 6 (1) (2024)
Sé Maria Frances, Louise Murray, Emma Nicklin, Galina Velikova, Florien W Boele
Long-term health-related quality of life in meningioma survivors: A mixed-methods systematic review. Neuro-oncology advances 6 (1) (2024)
Vicky Parmar, Johannes Haubold, Luca Salhöfer, Mathias Meetschen, Karsten Wrede, Martin Glas, Maja Guberina, Tobias Blau, Denise Bos, Anisa Kureishi, René Hosch, Felix Nensa, Michael Forsting, Cornelius Deuschl, Lale Umutlu
Fully automated MR-based virtual biopsy of primary CNS lymphomas. Neuro-oncology advances 6 (1) (2024)
Vicky Parmar, Johannes Haubold, Luca Salhöfer, Mathias Meetschen, Karsten Wrede, Martin Glas, Maja Guberina, Tobias Blau, Denise Bos, Anisa Kureishi, René Hosch, Felix Nensa, Michael Forsting, Cornelius Deuschl, Lale Umutlu
Fully automated MR-based virtual biopsy of primary CNS lymphomas. Neuro-oncology advances 6 (1) (2024)
Giacomo Sferruzza, Massimo Malcangi, Luca Bosco, Gaetano Finocchiaro
Reassessing the efficacy of bevacizumab in newly diagnosed glioblastoma: A systematic review and external pseudodata-based analysis. Neuro-oncology advances 6 (1) (2024)
Olha Krynina, Teresita Díaz de Ståhl, Cecilia Jylhä, Cecilia Arthur, Geraldine Giraud, Per Nyman, Anders Fritzberg, Johanna Sandgren, Emma Tham, Ulrika Sandvik
The potential of liquid biopsy for detection of the KIAA1549-BRAF fusion in circulating tumor DNA from children with pilocytic astrocytoma. Neuro-oncology advances 6 (1) (2024)
Samuel A Goldlust, Louis Burt Nabors, Sigmund Hsu, Nimish Mohile, Paul J Duic, Tara Benkers, Samuel Singer, Mayank Rao, Lori Cappello, Sandra L Silberman, George Farmer
Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma. Neuro-oncology advances 6 (1) (2024)
Angelo Dipasquale, Enrico Franceschi, Giuseppe Lombardi, Matteo Simonelli
Vorasidenib in IDH mutant WHO grade 2 gliomas: time to stop sitting on the fence? Neuro-oncology advances 6 (1) (2024)